As the Markets Waver, Here’s What We’ve Been Watching
zPremium - Greece unknowns weigh on the market going into the holiday weekend (Happy fourth by the way!), but the referendum on Sunday should offer some perspective … Continue Reading
PremiumzPremium - Greece unknowns weigh on the market going into the holiday weekend (Happy fourth by the way!), but the referendum on Sunday should offer some perspective … Continue Reading
PremiumResearch - Biotech is finally breaking out to new all-time highs, and you’ll be hard-pressed to find much red on your watch-list. We wrote about the current … Continue Reading
Read nowRecap - After a mostly red week, stocks gapped higher Friday morning with the latest jobs report. The jobless rate fell to 5.4%, the lowest since 2008, and a … Continue Reading
Read nowResearch - Even with Alexion Pharmaceuticals (ALXN) announcing Wednesday morning the acquisition of Synageva (GEVA) for a heady $8 billion, aggressive dip-buyers are still absent in the … Continue Reading
PremiumRecap - The biotech sector slipped all week before some green into Friday’s close. These dips are beginning to feel like the norm, though with every fresh … Continue Reading
Read nowResearch - It’s happened– the first high-profile failure from the re-emerging cohort of publicly traded gene therapy developers. Celladon (CLDN) reported on Sunday that MYDICAR, the company’s … Continue Reading
Read nowInsights - The talk of a bubble in biotech seems to have subsided (temporarily, no doubt), and the sector-tracking iShares Nasdaq Biotech ETF (IBB) has continued higher … Continue Reading
Read now